ArticleAdvanced healthcare materials2026
Bifunctional Surfaces With Immobilized Antibodies and Bioactive Peptides Mediate Selective Capture and Proliferation of Endothelial Colony-Forming Cells.
Article in Advanced healthcare materials, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Endothelial colony-forming cells (ECFCs) are of significant interest in vascular biomaterials engineering and cell-based therapies for cardiovascular diseases. Efficient isolation and expansion of ECFCs on polymeric surfaces either in vitro or in situ in the case of implants could significantly advance ECFC-based therapies. We present a novel bifunctional surface modification strategy combining oriented antibodies and extracellular matrix-derived peptides to selectively capture ECFCs on surfaces and then mediate firm adhesion, spreading and proliferation. Studies were conducted with anti-CD309 antibodies and custom RGD peptides, previously shown to respectively enable ECFC capture and clonal expansion. To aid in oriented antibody immobilization on surfaces while modulating antibody-RGD surface concentrations, Fc-binding peptides and RGD peptides were co-immobilized on aminated surfaces using click chemistry, followed by affinity-mediated antibody immobilization. Bifunctional anti-CD309 + RGD surfaces selectively captured ECFCs from a mixture with peripheral blood mononuclear cells in dynamic conditions. The presence of RGD peptides significantly enhanced cell spreading and proliferation, leading to additive effects on surface coverage under flow. Proof-of-concept studies demonstrated successful adaptation to 3D polystyrene microcarriers, showcasing potential scalability for clinical-grade cell production. The surface modification scheme provides a versatile and clinically translatable platform for advancing ECFC-based regenerative therapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.